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Abstract   
 
Background:  Prostate cancer is the second most common form of cancer affecting men 
today.  Currently, 98% of men diagnosed with prostate cancer survive for 10 or more 
years after being diagnosed with prostate cancer.  The prolonged course of the disease 
makes interventions aimed at improving quality of life an essential component of prostate 
cancer treatment.  There is a significant body of literature that suggests that support 
groups can improve the quality of life of cancer patients.  However, because the bulk of 
the studies regarding cancer support groups focused on women with breast cancer, it is 
unclear how applicable the results are to men with prostate cancer.   
 
Methods:  A thorough search of the medical literature was conducted using, Medline 
(Ovid), CINAHL, Google Scholar, and Web of Science with the keywords: prostate 
cancer, prostate neoplasm, support group, peer group, and self-help group.  Articles that 
reported primary data, included only men with prostate cancer, and measured changes in 
quality of life resulting from support group involvement were included.  All articles were 
assessed for quality using the Grading of Recommendations Assessment, Development 
and Evaluation (GRADE) system and assigned a rating of high, medium, low, or very 
low. 
 
Results:  Four studies met the criteria for inclusion in this review.  Three of the papers 
were randomized control trials and one was a cohort study.  Each of the studies used a 
different support group format and each of them found that support group participation 
resulted in statistically significant improvement in multiple areas related to quality of life.   
 
Conclusion:  Participation in a prostate cancer support group is likely to result in 
improved quality of life for men with prostate cancer.  At this time there is insufficient 
evidence to demonstrate the relative efficacy of one support group format over another; 
however, men are likely to receive some benefit regardless of format.  Given the low cost 
of support group participation and the low risk involved, it is reasonable to recommend 
that men with prostate cancer participate in a support group. 
 
Keywords:  Prostate cancer, support group, quality of life 
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Support Groups for Improving Quality 
of Life in Men with Prostate Cancer 
 
BACKGROUND 
 
Improvements in the detection and treatment of prostate cancer have led to 
growing numbers of men living with prostate cancer.  In 2010, there was estimated to be 
over 2.6 million men living with prostate cancer in the United States.
1
  In 2013, 
approximately 238 590 additional men will be diagnosed with prostate cancer making it 
the second leading cause of cancer in men.
2
  Men with prostate cancer are also living 
longer after being diagnosed with prostate cancer.  Currently, the 5-year survival rate for 
prostate cancer is 99% and the 10-year survival rate is 98%.
2
  As the numbers, and life 
expectancy, of men living with prostate cancer continue to increase, finding interventions 
to improve the quality of life for men living with prostate cancer is becoming 
increasingly important. 
Prostate cancer and its treatment can lead to a number of complications that 
negatively impact quality of life.  Prostate cancer is associated with three major disease-
specific problems, specifically urinary incontinence, sexual dysfunction, and bowel 
dysfunction.
3
  Prostate cancer is also associated with a number of general problems that 
impact quality of life including, but not limited to, anxiety and depression, bodily pain, 
loss of vitality, poorer social and emotional well-being, diminished mental and physical 
functioning, financial burdens, and reduced capacity to work.
3
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Social support is an important contributor to health and well-being that can 
mitigate the impact of stressors, including those caused by illness.  There is a growing 
body of work that suggests that support groups are an effective way to provide social 
support to patients with cancer and increase their quality of life.
4
  Several theories have 
been developed to attempt to explain how support groups improve quality of life.
5
  The 
stress and coping theory suggests that social support enhances coping skills and mediates 
the stress response.
6,7,8
  The social comparison theory posits that participation in support 
groups normalizes experiences, encourages health promoting behaviors, enhances self-
esteem, and provides positive role modeling.
9,10
  The helper-therapy principle holds that 
support groups enhance self-esteem by providing an opportunity to help other people in 
similar circumstances rather than to simply focus on their own problems.
11
  
A well-written review of literature
4
 regarding support groups raised questions 
about the applicability of this methodology to people affected by cancers other than 
breast cancer.  Most of the literature regarding support groups has focused on women 
with breast cancer.  As this cohort of women has arguably the greatest visibility and 
social support of any group of cancer patients, it is uncertain that patients with other 
forms of cancer will receive the same quality of life improvements as a result of support 
group participation.  Further, gender differences may have an impact on the rate of 
participation in, and the amount of benefit received from, support groups. There is 
research to suggest that men are less likely than women to participate in cancer support 
groups.  A study
12
 of women with breast cancer and men with prostate cancer found that 
33% of women with breast cancer had attended a support group as opposed to just 13% 
of men with prostate cancer.  Men are also less likely to seek social support amongst their 
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group of friends and family.  Harrison et al
13
 found that men are more likely to share their 
concerns with just one confidante while women are more likely to confide in their 
friends, family, and intimate partner.  Dean et al
14
 suggest that men may be less inclined 
to share their feelings with others because socialization and social norms cause men to 
contain their emotions.    
There is also some data to suggest that providers are less likely to inform prostate 
cancer patients about support groups than breast cancer patients.  Krizek et al
12
 found that 
71% of breast cancer patients were told about support groups as opposed to only 56% of 
men with prostate cancer.  However they found that a significant number of patients that 
are told about support groups will attend.  Of the men told about prostate cancer support 
groups, 24% reported attending at least once.  The average number of meetings attended 
for men was 10.6 meetings over an average period of 15.2 months.
12
  
Due to the numerous differences between the cohorts of women with breast 
cancer and men with prostate cancer, the bulk of the research regarding support group 
involvement may be inapplicable to men with prostate cancer.  The purpose of this 
literature review is to identify and assess the primary research regarding the efficacy of 
support groups for men with prostate cancer.  
 
 
METHODS 
 
A thorough search of medical literature was conducted using, Medline (Ovid), 
CINAHL, Google Scholar, and Web of Science.  Results were limited to men already 
diagnosed with prostate cancer by combining the terms ‘prostate cancer’ and ‘prostate 
neoplasm’ using the ‘or’ function.  To find articles focused on various support group 
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formats, the search terms ‘support group’, ‘peer group’, and ‘self-help group’ were 
combined using the ‘or’ function.  These two sets of search results were then combined 
using an ‘and’ statement and the results were limited to articles that were published in 
English.  The remaining articles were reviewed to ensure that they met all of the inclusion 
criteria which included, 1) reported primary data, 2) included only men with prostate 
cancer, 3) studies designed to detect changes in quality of life measures as a result of 
support group participation. The articles that met the inclusion criteria were assessed for 
quality using the Grading of Recommendations Assessment, Development and 
Evaluation (GRADE) system and assigned a rating of high, medium, low, or very low.
15
  
See Table I.   
 
RESULTS 
 
The initial search yielded 212 results.  The results were screened using the 
inclusion criteria described above and four articles were selected for inclusion in this 
review.  Of the four studies, three of them were randomized controlled trials
16,17,18
 and 
one was an observational study.
19
  Each of the studies used a different support group 
format, and each of them found that there was a statistically significant improvement in 
one or more quality of life measures as a result of support group participation. 
 
Osei et al (2013) 
Osei et al
16
 performed a randomized controlled trial comparing the effects of 
participation in an online support group with an educational resource kit on quality of life 
in men with prostate cancer.  In this trial, 40 men were asked to complete a baseline 
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quality of life survey before being randomized into an experimental and control group.  
Men randomized to the experimental group were asked to participate in an online support 
group at least three times per week for six weeks.  Men randomized to the control group 
received a collection of educational pamphlets which included information about various 
topics related to prostate cancer and its treatment.  Both groups completed additional 
quality of life surveys at 6 and 8 weeks after the baseline measurement.
16
 
The researchers sent letters to 1000 men identified through the California Region 
5 Desert Sierra Cancer Surveillance Program requesting their participation in the study.  
To be included in the study, the participants were required to meet the inclusion criteria 
which included, 1) diagnosed with prostate cancer within 5 years of the study, 2) English 
literacy, 3) access to internet and email, 4) being between the ages of 40 and 85, and 5) 
being married or living with a significant other.   Of the 51 men that responded, 11 were 
excluded from participation due to death of the patient (n = 2), travel plans that barred 
participation (n = 3), lack of adequate internet access (n = 4), and language barriers that 
prevented participation in the support group (n = 2).  The remaining men were arranged 
into pairs based on similarity of demographic data and a member of each pair was 
randomized to the experimental and control group.
16
   
After the men were randomized, but before they were notified of their group 
assignment, they were sent a link to complete a baseline survey online.  After the survey 
was complete the men were notified electronically of their group assignment.  Men 
assigned to the experimental group were sent a link to the Us TOO International Web site 
(www.ustoo.org) and were asked to participate in the prostate cancer education and 
support program offered on the organization’s website at least three times per week for 6 
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weeks.  Men randomized to the control group were mailed a prostate cancer resource kit 
that contained educational materials provided by Us Too International.
16
   
Quality of life was measured at baseline, 6 weeks, and 8 weeks using four tools, 
the SF-12, the EPIC-26, the Satisfaction with Life Scale, and the Relationship 
Satisfaction Questionnaire.  In addition, at 8 weeks the men in the experimental group 
were asked to rate their level of satisfaction with the online support group using a survey 
designed by the investigators.  The SF-12 is a 12 item survey that is derived from the SF-
36.  Both surveys assess 8 dimensions of health.  Possible scores range from 0 to 100 
with higher scores indicating better health.
20
  The Expanded Prostate Cancer Index 
Composite (EPIC-26) is a 26 item survey used to assess health-related quality of life in 
men with prostate cancer.
21
  It assesses five domains of health including 1) urinary 
irritation/obstruction, 2) urinary incontinence, 3) bowel health, 4) sexual health, and 5) 
hormonal health.  Possible scores range from 0 to 100 with higher scores indicating better 
health.  The Satisfaction with Life Scale is a five item survey that used a seven response 
scale ranging from strongly agree to strongly disagree.
22
  The mean of the response was 
used to generate a score ranging from 1 to 7 with a higher score indicating a higher 
satisfaction with life.  The relationship satisfaction questionnaire assesses 12 items on a 4 
point scale to measure relationship satisfaction of spousal relationships.
23
  Possible scores 
range from 1 to 4 with higher scores indicating greater satisfaction with the spousal 
relationship. 
The men in the experimental group showed statistically significant improvement 
in three health-related quality of life categories: 1) urinary irritation and obstruction 
health, 2) sexual health, and 3) hormonal health.  All three of these measures showed 
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increases between the baseline measurement and the 6 week measurement that had 
returned to baseline by the 8 week measurement.  The experimental group began with a 
mean urinary irritation/obstruction health score of 85.51 which increased to 91.33 at 6 
weeks and fell to 85.22 at 8 weeks.  The mean sexual health score for the experimental 
group was 33.92 at baseline, rose to 47.80 at 6 weeks, and dropped to 20.57 at 8 weeks.  
The experimental group’s baseline hormonal health score was 82.36 which increased to 
89.50 at 6 weeks and fell to 81.27 at 8 weeks.
16
  See Table II. 
 
Weber et al (2004)  
Weber et al
17
 performed a randomized controlled trial comparing the effects of 
one-on-one support sessions and the usual standard of care.  Prior to the beginning of the 
study, 10 long-term prostate cancer survivors were selected to be support partners.  They 
were required to have prostate cancer for at least 3 years and have a stable prostate 
specific antigen (PSA) measurement, indicating continuing remission, at the time of the 
experiment.  The support partners were further required to have undergone a radical 
prostatectomy that resulted in urinary and sexual dysfunction as part of their treatment, 
speak English fluently, and be willing to share their life experiences with the study 
participants.  They then received 2 hours of training to develop skills required to conduct 
one-on-one support sessions. 
One hundred men were contacted after their 6 week follow up visit following a 
radical prostatectomy.  To be eligible for the study, the men had to have sexual and 
urinary side effects resulting from their prostatectomy, have no prior history of cancer, 
not be considered terminally ill, have no recent loss of a loved one, and speak fluent 
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English.  Of those that were contacted, 30 men met the inclusion criteria, agreed to 
participate in the study, and were able to travel to the meetings.  The 30 participants were 
randomized to either a control group which did not participate in any support sessions, or 
to the experimental group which was paired with a dyad with similar demographic 
characteristics to minimize the impact of cultural differences.  The participants met with 
their support partners eight times over the course of 8 weeks at coffee shops where they 
could have private conversations.  The support partners kept careful logs of the duration, 
content, and quality of the meetings. 
The participants completed five different surveys over the course of the study that 
measured social support, self-efficacy, depression, incontinence and erectile dysfunction, 
and comorbidities that can contribute to symptoms of depression.  The Modified 
Inventory of Socially Supportive Behaviors was used to measure social support.  This 
survey assessed 41 items on a scale from 0 to 4 with total scores ranging from 0 to 164.  
Higher total scores indicated greater social support.
24
  Self-efficacy was measured using 
the Stanford Inventory of Cancer Patient Adjustment.  Participants rated 38 items from 0 
to 10 the total scores ranging from 0 to 380.
25
  To measure depression, the participants 
filled out the short version of the Geriatric Depression Scale (GDS).  The GDS is a 
survey that uses 15 yes or no questions to distinguish between somatic complaints 
stemming from illness and symptoms of depression.
26
  The GDS has a range of scores 
from 0 to 15 with higher scores indicating greater depression.  The University of 
California, Los Angeles Prostate Cancer Index (UCLA PCI) was used to measure health-
related quality of life in 6 categories, urinary function and bother, bowel function and 
bother, and sexual function and bother.
27
  Each category on the UCLA PCI is scored from 
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0 to 100 with higher scores indicated better function or less bother.  The Charlson Index 
was used to determine the psychological and physiologic burden imposed by the 
participants’ comorbidities.28  Higher scores are associated with greater comorbid 
conditions that may cause depressive symptoms.   
The men in the experimental group showed statistically significant improvement 
in quality of life relative to the control group in 3 of the categories measured, 1) self-
efficacy, 2) depression, and 3) bother by sexual side effects.  The mean self-efficacy 
scores for the experimental group was 290.3 at baseline and rose to 314.9 after 8 weeks.  
The mean depression score was 2.2 at baseline and decreased to 0.3 at the 4 week 
measurement and increased to 0.4 at the 8 week measurement.  Analysis of the data 
showed that this constituted a statistically significant difference between the experimental 
and control groups at the 4 week measurement; however, the difference between the two 
groups was no longer statistically significant at the 8 week measurement.  Finally, when 
the data was analyzed, the experimental group had a statistically significant improvement 
in sexual bother over the control group (t=2.6, p=0.014).  See Table III. 
 
Lepore et al (2003) 
Lepore et al
18
 conducted a randomized controlled trial comparing an educational 
lecture series without an open discussion period, an education lecture series that included 
an open discussion period, and the standard of care.  Men who had been treated for 
localized prostate cancer were recruited from 11 Pittsburgh area clinics and hospitals.  To 
be eligible for inclusion in the study the men had to have no prior history of cancer, live 
within a 1 hour driving distance from the intervention site, and have non-metastatic 
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disease at the time of diagnosis.  Of the 576 men that were referred to the study 279 met 
the inclusion criteria, completed the baseline surveys and agreed to randomization.  The 
men were randomized into one of three groups, a control group, an education only group, 
and an education plus facilitated peer discussion group.  The men in the education only 
group attended six weekly 1 hour lectures on various topics relating to prostate cancer.  
At each education session, 10 minutes was allotted for question and answer sessions but 
discussion between men attending the sessions was discouraged.  Men randomized to the 
education plus facilitated peer discussion group were given the same six weekly 1 hour 
lectures, however, they participated in a 45-minute group discussion facilitated by a male 
clinical psychologist after each lecture.  Men in the control group received nothing in 
addition to the normal standard of care. 
The men were interviewed at four times during the course of the study, once 
before being randomized, and at 2 weeks, 6 months, and 12 months after completion of 
the intervention.  The researchers used various surveys to detect differences in six areas, 
1) prostate cancer knowledge, 2) health related behavior, 3) general quality of life, 4) 
depression, 5) disease specific quality of life, and 6) employment.  Prostate cancer 
knowledge was assessed at baseline at the first post-intervention interview.  It consisted 
of a 13 question true/false quiz covering various topics related to prostate cancer with 
higher scores indicating greater knowledge.  Health behavior was assessed using a 5 
question survey that measured the frequency with which men exercised, performed Kegel 
exercises, took time to relax, took vitamins, and got adequate sleep.  A health behavior 
index score was calculated based on responses with a range of 5 to 33 with higher scores 
indicating greater engagement in healthy behavior.  General quality of life was measured 
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using the SF-36.   The SF-36 survey measures eight domains of quality of life including 
vitality, physical functioning, bodily pain, general health perceptions, physical role 
functioning, emotional role functioning, social role functioning, and mental health.
29
  
Each domain is assigned a score ranging from 0 to 100 with higher scores indicating 
better health or functioning.  Depressive symptoms were measured using a 15 item 
variation of the Center for Epidemiological Studies Depression Scale (CES-D).  The 
CES-D rates depressive symptoms using a score ranging from 0 to 3 with higher scores 
indicating greater depressive symptoms.
30
  Disease specific quality of life was assessed 
using the University of California, Los Angeles Prostate Cancer Index (UCLA PCI) 
described above.  Each category on the UCLA PCI is scored from 0 to 100 with higher 
scores indicated better function or less bother.  Employment status was determined at 
each interview. 
Analysis of the data showed that both of the interventions led to statistically 
significant improvement in prostate cancer knowledge, participation in positive health 
behaviors, and physical function over the control group.  Although the effect was not 
large enough to be statistically significant, the education plus discussion group showed 
relatively more improvement in all of these areas over the group that received education 
alone.  In addition, the education plus discussion group showed statistically significant 
improvements in employment and bother from sexual dysfunction.   
Another trend that was discovered upon statistical analysis of the data was that 
men with less formal education, as measured by having a college degree, tended to 
receive greater benefit from the interventions than men who had college degrees.  This 
trend was particularly evident in two areas, improvements in healthy behavior, and 
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physical functioning.  Men without college degrees showed significant improvement in 
physical functioning as a result of both interventions, while men with college degrees 
showed no significant improvement in this area.  Similarly, men without college degrees 
showed significant improvements in healthy behaviors as a result of participation in the 
interventions while their peers with college degrees did not.  See Table IV. 
 
Katz et al (2002) 
Katz et al
19
 performed a cohort study that compared demographic characteristics, 
and health related quality of life, in men attending prostate cancer support groups with 
that of men that were enrolled in a prostate cancer database.  They recruited 96 Men with 
prostate cancer from 10 support groups in the San Francisco area.  To be eligible the men 
were required to be over 18 years old, have biopsy proven prostate cancer, and have 
attended at least one support group meeting.  Numerous quality of life measures of men 
attending support groups were compared to those of men enrolled in Cancer of the 
Prostate Strategic Research Endeavor (CaPSURE) database.  The CaPSURE database is a 
longitudinal, observational database that registers men with biopsy proven prostate 
cancer from 35 urology practices across the United States.
31,32
  To be eligible for 
comparison, men in the CaPSURE database were required to have at least 1 year of 
follow up, have completed a health-related quality of life questionnaire at the last follow 
up, and not have selected active surveillance as the sole intervention for their prostate 
cancer.  Of the 6969 men enrolled in the CaPSURE database at the time the study was 
conducted, 1966 men qualified and were included in the analysis.   
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Two instruments were used to measure health-related quality of life, the RAND 
SF-36 Health Survey (SF-36), and the UCLA PCI.  Both the SF-36 and the UCLA PCI 
grade each scale from 1 to 100 with higher scores indicating better health or functioning.   
When the data were analyzed, the researchers found several statistically 
significant differences between the two groups of men.  The results from the SF-36 
survey identified four areas where men in support groups had statistically significant 
improvements in health-related quality of life, physical function role, vitality/fatigue, 
general health and mental health.  The data from the UCLA PCI surveys identified four 
areas with statistically significant improvements in the experimental group, sexual 
function, sexual bother, urinary bother, and bowel bother.   
Comparison of the demographic characteristics of the two groups showed that, 
although there were no differences between the two groups in terms of ethnicity or age, 
the men that attended support groups tended to have higher annual incomes and 
education levels than men in the CaPSURE database.  Only 7.5% of the men enrolled in 
support groups had no college education while 43.5% of the men enrolled in the 
CaPSURE database had never attended college.  They also found that 41.8% of men 
attending support groups made over $50 000 per year as opposed to only 16.1% of men 
in the CaPSURE database.  Men in the CaPSURE database were more likely to be living 
in poverty with 41.6% having a household income below $20 000 a year compared to 
only 14% of men in support groups.  They also found that men in support groups tended 
to receive more treatment than men in the CaPSURE database with 69.4% of the support 
group participants receiving more than one form of treatment as opposed to just 35.9% of 
men in the CaPSURE database.  See Table V. 
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DISCUSSION 
 
Implications for Clinical Practice 
Although each of the four studies
16,17,18,19
 included in this review used different 
support group formats, all of the studies demonstrated statistically significant 
improvement in multiple quality of life measures.  The agreement across all of the studies 
constitutes strong evidence in favor of the positive impact of support groups for men with 
prostate cancer.  Further, the findings of these studies suggest that the larger body of 
work regarding cancer support groups can be applied to men with prostate cancer.  These 
four studies, when considered in the context of the rest of the literature pertaining to 
cancer support groups, provide compelling evidence that cancer patients, including men 
with prostate cancer, can garner significant quality of life improvements from 
participation in support groups.  
 Two studies
18,19
 demonstrate that men with lower levels of formal education and 
lower socioeconomic status are less likely to participate in support groups but receive 
greater benefit from participation.  Katz et al
19
 found that men with lower socioeconomic 
status and less formal education are less likely to use support groups than their peers.  
Lepore et al
18
 found that men with less formal education tend to receive more benefit 
from support group participation.  Men without a college degree showed significant 
improvements in positive health behaviors and improvements in physical functioning that 
were not evident in men with college degrees.  These findings suggest that this group of 
men in particular should be encouraged to participate in support groups. 
Based on these studies alone, it is not possible to make strong recommendations 
for one support group format over another.  However, the consistent improvements in 
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quality of life, despite support group format, suggests that any type of support group that 
a patient is comfortable participating in is likely to be beneficial.  When making 
recommendations regarding prostate cancer support groups, providers should consider 
providing a menu of options to patients as compliance is more likely to be a determinant 
of outcome than support group format.   
Ideally, providers would provide patients with information regarding support 
groups as close to the time of diagnosis as possible.  There are a variety of treatment 
approaches available to men with prostate cancer that are associated with serious side 
effects.  Support groups can provide men with a host of knowledge regarding a variety of 
treatment options and side effects that may better prepare patients to face challenging 
treatment decisions.  Patients with lower levels of education and medical literacy in 
particular may benefit from early involvement in support groups. 
 
Limitations of the Studies 
Due to the nature of the intervention being tested, there is an inherent lack of 
blinding to all of the studies as there is no way to blind the participants to the intervention 
that they’re receiving.  The lack of blinding may introduce bias into the results of the 
study and has the potential to lead to an overestimation of the effect of the intervention.  
Participants that are not selected to be in the experimental group may report lower quality 
of life scores based on disappointment from being excluded from the intervention.  
Likewise, participants selected for the experimental group may report higher quality of 
life scores out of excitement for being included in the experimental group.  Further, 
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members of both groups may be inclined to provide investigators with the responses that 
they believe they are looking for.      
The randomized controlled trial conducted by Osei et al
16
 had two significant 
shortcomings that diminish the quality of evidence.  First, the intervention only lasted six 
weeks and the outcomes were only measured for eight weeks.  Both the intervention and 
the observational period may be too short to detect changes in quality of life outcomes.  
Further, the experiment was not sufficiently long to detect any long term impact that the 
intervention had.  Secondly, the study had a very low response rate with only 51 of the 
1000 men that were contacted responding.  This led to a sample size that may have been 
too small to detect all of the treatment effects.   
The randomized controlled trial performed by Weber et al
17
 also had three 
significant limitations that may have introduced bias into the results.  First, the sample 
size was small with just 15 men randomized to the experimental group.  The small 
sample size impacts the study’s ability to detect small treatment effects.  Second, the 
sample was not representative of the cohort of men with prostate cancer.  The men 
included in the study had all undergone radical prostatectomy and the majority of the 
participants were white, married, well educated, and made over $50 000 per year.  The 
demographics of the experimental group raise questions regarding the generalizability of 
the results to all men with prostate cancer.  Finally, the study was only eight weeks long 
and as a result, was not sufficiently long to detect long term impacts of support group 
participation.   
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The study conducted by Lepore et al
18
 had the best design of the three randomized 
controlled trials included in this study.  Aside from the inherent lack of blinding, there 
were no significant methodological limitations.   
The cohort study conducted by Katz et al
16
 had only one methodological problem, 
however, it would likely lead to an underestimation of the treatment effect and therefore 
does not significantly impact the applicability of the results.  Cohort trials, by virtue of 
being observational trials, provide a lower level of evidence than randomized controlled 
trials as they have a higher inherent risk of bias.  The one methodological shortcoming of 
the study was the lack of screening of the men in the CaPSURE database for support 
group participation to ensure that members of the control group were not exposed to the 
intervention.  However, this limitation is likely to lead to the underreporting of the 
treatment effect and does not represent a significant limitation of the study.   
 
CONCLUSION 
 
The four studies
16,17,18,19
 included in this review, when taken as a whole, provide 
compelling evidence that men with prostate cancer benefit from participation in support 
groups.  In addition, support groups have low or no cost of participation and involvement 
is associated with little risk.  In light of the low cost and limited risk, providers should 
have a relatively low threshold for recommending support groups to their patients with 
prostate cancer.   
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Table I. Characteristics of Reviewed Studies 
 
Quality Assessment 
Study Design 
Downgrade Criteria Quality of 
Evidence Limitations Indirectness Imprecision Inconsistency Publication bias likely 
Osei et al
16
  
Randomized 
Controlled 
Trial 
Very 
Serious
a,b Not Serious Serious
c 
Not Serious Not Likely Very Low 
Weber et al
17
  
Randomized 
Controlled 
Trial 
Very 
Serious
a,b
 
Not Serious Serious
c
 Not Serious Not Likely Very Low 
Lepore et al
18
  
Randomized 
Controlled 
Trial 
Serious
a
 Not Serious Serious
c
 Not Serious Not Likely Moderate 
Katz et al
19
  
Cohort Study Not Serious
d 
Not Serious Not Serious Not Serious Not Likely Moderate 
a Neither the participants nor the experimenters were blinded to group allocation, 
b Studies were a short duration 
c Small sample size  
d All plausible confounding would reduce the demonstrated effect 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 - 26 -  
Table II. Data from Osei et al 
 
 
 
Variable Group 
 Control 
Mean (95% CI) 
Experimental 
Mean (95% CI) 
Perceived Mental Health   
Baseline 46.61 (43.82-49.40) 45.79 (43.00-48.58) 
6 Weeks 40.64 (37.92-43.36) 45.24 (42.51-47.96) 
8 Weeks 45.39 (42.47-48.31) 45.70 (42.78-48.62) 
Life Satisfaction    
Baseline 5.31 (4.74-5.88) 5.21 (4.64-5.78) 
6 Weeks 3.54 (2.93-4.16) 5.35 (4.73-5.96) 
8 Weeks 5.24 (4.46-6.01) 4.34 (3.57-5.12) 
Perceived Physical Health   
Baseline 55.99 (52.78-59.19) 52.96 (49.76-56.17) 
6 Weeks 42.44 (38.55-46.33) 51.25 (47.36-55.13) 
8 Weeks 53.96 (49.65-58.28) 47.36 (43.05-51.68) 
Spouse Positive   
Baseline 3.81 (3.65-3.97) 3.66 (3.50-3.83) 
6 Weeks 3.15 (2.84-3.47) 3.42 (3.11-3.74) 
8 Weeks 3.75 (3.51-3.99) 3.44 (3.20-3.68) 
Spouse Negative   
Baseline 1.57 (1.41-1.73) 1.66 (1.50-1.82) 
6 Weeks 2.04 (1.80-2.29) 1.70 (1.45-1.94) 
8 Weeks 1.62 (1.48-1.76) 1.68 (1.54-1.82) 
Urinary Incontinence Health   
Baseline 72.48 (65.08-79.87) 73.06 (65.66-80.46) 
6 Weeks 72.01 (67.71-76.32) 69.60 (65.30-73.90) 
8 Weeks 72.05 (64.23-79.87) 65.94 (58.12-73.76) 
Urinary Irritation/Obstruction 
Health  
  
Baseline 91.99 (86.88-97.31) 85.51 (80.19-90.82) 
6 Weeks 82.42 (76.16-88.68) 91.33 (85.07-97.59) 
8 Weeks 88.53 (81.90-95.16) 85.22 (78.59-91.85) 
Sexual Health    
Baseline 43.97 (32.89-55.05) 33.92 (22.84-45.00) 
6 Weeks 18.80 (9.69-27.92) 47.80 (38.68-56.91) 
8 Weeks 30.32 (19.72-40.91) 20.57 (9.97-31.16) 
Hormonal Health   
Baseline 88.64 (82.25-95.04) 82.36 (75.96-88.75) 
6 Weeks 65.75 (58.60-72.90) 89.50 (82.35-96.65) 
8 Weeks 90.23 (83.75-96.70) 81.27 (74.80-87.75) 
Bowel Health    
Baseline 98.21 (94.13-102.2) 94.92 (90.84-98.99) 
6 Weeks 96.29 (92.88-99.71) 97.04 (93.63-100.50) 
8 Weeks 95.85 (91.03-100.67) 95.61 (90.79-100.43) 
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Table III. Data from Weber et al 
 
Variable Group 
 Control (n=15)  
Mean (S.D.) 
Experimental (n=15) 
Mean (S.D.) 
Depression   
Pre-test 1.7 (2.2) 2.2 (3.3) 
4 weeks 1.7 (1.7) 0.3 (0.6) 
Post-test 2.1 (2.3) 0.4 (0.8) 
Self-efficacy   
Pre-test 319.5 (37.5) 290.3 (40.6) 
Post-test 309.7 (36.5) 314.9 (26.3) 
Self-efficacy Emotional 
Sub-Scale  
  
Pre-test 77.7 (10.4) 69.1 (12.1) 
4 weeks 78.9 (8.2) 76.1 (5.9)  
Post-test 74.8 (11.2) 75.7 (6.7) 
Social Support   
Pre-test 101.7 (17.9) 98.2 (11.8) 
Post-test 100.7 (17.3) 95.5 (11.1) 
   
Pre-test Comorbidity 0.4 (0.6) 0.5 (0.8) 
Urinary Function   
Pre-test 57.9 (23.9) 35.5 (18.9) 
Post-test 74.0 (28.6) 57.0 (26.8) 
Urinary Bother   
Pre-test 50.0 (31.3) 40.0 (28.0) 
Post-test 66.6 (38.6) 63.3 (26.5) 
Sexual Function   
Pre-test 8.5 (6.8) 11.6 (11.4) 
Post-test 13.0 (16.4)  20.4 (13.5) 
Sexual Bother   
Pre-test 51.7 (40.6) 26.7 (35.9) 
Post-test 56.7 (41.7) 26.7 (32.0) 
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Table IV. Data from Lepore et al 
 
Variable Group Assignment 
 Control 
Mean (S.D.) 
Education 
Mean (S.D.) 
Education plus Discussion 
Mean (S.D.) 
Depressive Symptoms    
Baseline 0.46 (0.52) 0.54 (0.45) 0.49 (0.48) 
2 weeks post 0.38 (0.48) 0.50 (0.39) 0.37 (0.36) 
6 months post 0.40 (0.52) 0.41 (0.41) 0.39 (0.41) 
12 months post 0.40 (0.49) 0.43 (0.42) 0.35 (0.44) 
Health Behaviors    
Baseline 20.88 (4.36) 20.74 (4.34) 20.59 (3.77) 
2 weeks post 19.95 (3.97) 20.38 (4.18) 21.34 (3.72) 
6 months post 17.77 (3.80) 18.70 (3.89) 19.19 (4.04) 
12 months post 18.47 (3.97) 18.81 (3.75) 18.52 (3.87) 
Mental Functioning    
Baseline 51.03 (9.89) 50.18 (8.24)  50.73 (8.54) 
2 weeks post 53.69 (9.10) 52.80 (7.48) 53.20 (8.20) 
6 months post 53.55 (9.01) 52.28 (8.56) 53.07 (8.09) 
12 months post 53.42 (8.90) 53.07 (7.21) 53.95 (7.48) 
Physical Functioning     
Baseline 44.82 (9.17) 46.54 (8.14) 46.91 (7.73) 
2 weeks post 49.15 (9.69) 51.41 (6.47) 51.55 (7.52) 
6 months post 47.19 (10.39) 48.38 (7.99) 50.55 (6.96) 
12 months post 47.42 (10.77) 48.25 (9.43) 49.39 (8.25) 
Urinary Function    
Baseline 60.13 (27.15) 64.13 (29.13) 60.35 (29.68) 
2 weeks post 75.11 (21.94) 75.53 (21.65) 75.43 (23.21) 
6 months post 82.58 (19.23) 79.78 (18.89) 81.69 (20.03) 
12 months post 83.00 (18.26) 84.25 (18.77) 83.44 (19.17) 
Urinary Bother    
Baseline 60.31 (32.73) 55.95 (30.46) 55.81 (33.36) 
2 weeks post 75.32 (29.55) 77.16 (24.43) 76.45 (31.24) 
6 months post 82.91 (24.53) 79.57 (24.26) 81.47 (25.34) 
12 months post 84.81 (24.16) 84.82 (23.29) 83.14 (24.98) 
Sexual Function    
Baseline 20.51 (25.51) 17.13 (21.20) 19.41 (24.33) 
2 weeks post 24.04 (22.62) 19.33 (21.63) 24.16 (26.33) 
6 months post 26.30 (26.01) 25.69 (28.11) 28.69 (28.27) 
12 months post 28.89 (27.87) 27.14 (28.47) 34.24 (30.62) 
Sexual Bother     
Baseline 45.25 (40.05) 41.87 (40.60) 46.69 (39.58) 
2 weeks post 35.76 (37.70) 40.63 (39.25) 50.58 (37.57) 
6 months post 33.86 (37.35) 38.44 (39.37) 46.73 (39.91) 
12 months post 37.99 (37.52) 49.10 (37.94) 56.18 (38.17) 
Bowel Function    
Baseline 83.37 (18.56) 79.46 (18.46) 82.55 (17.60) 
6 months post 89.57 (14.06) 86.38 (13.19) 88.01 (14.07) 
12 months post 89.33 (13.85) 88.35 (14.18) 90.50 (11.19) 
Bowel Bother    
Baseline 81.56 (26.39) 76.19 (25.71) 82.85 (24.63) 
2 weeks post 88.29 (19.13) 88.27 (18.99) 87.50 (20.20) 
6 months post 87.34 (22.60) 85.54 (20.70) 88.24 (18.33) 
12 months post 88.92 (21.09) 89.29 (19.90) 90.41 (17.22) 
Quiz % Correct    
Baseline 31.06 (22.65) 35.60 (23.27) 35.62 (23.05) 
2 weeks post 36.71 (21.65) 53.58 (25.21) 53.18 (25.78) 
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Table V. Data from Katz et al 
 
Variable Group 
 Support Groups CaPSURE 
Mental Health    
No. of Respondents  84 2236 
Mean (Range) 81.7 (32-100) 77.7 (0-100) 
Emotional Role   
No. of Respondents  90 2211 
Mean (Range) 85.9 (0-100) 77.9 (0-100) 
Social Functioning   
No. of Respondents  88 2236 
Mean (Range) 90.3 (25-100) 84.4 (0-100) 
General Health    
No. of Respondents  88 2249 
Mean (Range) 77.6 (8.3-100) 67.0 (0-100) 
Vitality/Fatigue   
No. of Respondents  84 2235 
Mean (Range) 70.8 (0-100) 61.7 (0-100) 
Physical Functioning   
No. of Respondents  88 2235 
Mean (Range) 88.2 (0-100) 76.5 (0-100) 
Physical Role   
No. of Respondents  90 2209 
Mean (Range) 83.6 (0-100) 66.3 (0-100) 
Bodily Pain   
No. of Respondents  88 2237 
Mean (Range) 90.2 (37-100) 83.1 (0-100) 
Urinary Function   
No. of Respondents  93 2261 
Mean (Range) 82.2 (0-100) 78.6 (0-100) 
Urinary Bother   
No. of Respondents  92 2230 
Mean (Range) 78.8 (0-100) 73.4 (0-100) 
Sexual Function   
No. of Respondents  94 2208 
Mean (Range) 31.7 (0-90.63) 21.3 (0-100) 
Sexual Bother   
No. of Respondents  92 2069 
Mean (Range) 57.6 (0-100) 42.5 (0-100) 
Bowel Function   
No. of Respondents  94 2237 
Mean (Range) 86.2 (39.25-100) 84.2 (6.25-100) 
Bowel Bother   
No. of Respondents  92 2221 
Mean (Range) 86.7 (25-100) 81.4 (0-100) 
 
